(Press-News.org) SAN DIEGO - Pediatric research discoveries over the past 40 years haveled to prevention and treatment strategies that have saved millions of lives worldwide. Seven of the greatest research achievements will be presented on Sunday, April 26 at the Pediatric Academic Societies annual meeting at the San Diego Convention Center.
"Today, we often take these research discoveries for granted," said presenter Tina Cheng, MD, MPH, FAAP, chair of the American Academy of Pediatrics Committee on Pediatric Research. "Because of research and science in these seven areas, American children are healthier and safer today and will grow up to be healthier adults."
The research achievements include:
1. Preventing diseases, such as rotavirus and Haemophilus influenzae type b (Hib), with life-saving immunizations.
2. Saving premature babies by helping them breathe.
3. Reducing sudden infant death syndrome (SIDS) with the Back to Sleep campaign, which urged parents and caregivers to put babies to sleep on their backs.
4. Curing acute lymphocytic leukemia, a common childhood cancer.
5. Preventing HIV transmission from mother to baby.
6. Increasing life expectancy for children with chronic diseases such as sickle cell disease and cystic fibrosis.
7. Saving lives with car seats and seat belts.
These seven achievements will be highlighted in a short video that will debut during the opening plenary session of the Pediatric Academic Societies meeting, kicking off a campaign by the AAP to promote child health research. The video and campaign information is available online at http://www.aap.org/7Achievements. Journalists who would like interviews with the families featured in the video, or physicians who have worked in these fields of research, should contact PAS Media Relations.
There are many vaccines that have saved millions of lives, said Dr. Cheng, professor of pediatrics and public health, and chair of pediatrics, Johns Hopkins Bayview Medical Center.
"An example is the Hib vaccine for Haemophilus influenzae, a dangerous bacteria," she said. "When I was an intern not thatmany years ago, the hospital ward had plenty of kids with serious infections like meningitis from Haemophilus influenzae. Today, because of the Hib vaccine, current doctors in training, my interns, have never seen a case."
Another example of a life-saving intervention is putting babies to sleep on their backs instead of their stomachs. This discovery has decreasedthe SIDS rate by one half,said Dr. Cheng,who also is vice chair, Department of Pediatrics, Johns Hopkins School of Medicine, and division chief, General Pediatrics and Adolescent Medicine, Johns Hopkins University School of Medicine, Bloomberg School of Public Health.
"We have come a long way," Dr. Cheng said. "But we also have further to go in understanding how to prevent and cure disease. There is a need for new knowledge, new vaccines and new therapies to maintain health and cure disease. It requires continued research."
Dr. Cheng will present "Great Achievements in Pediatric Research" from at 2:05-2:30 p.m. PT Sunday, April 26, during the American Academy of Pediatrics (AAP) plenary.
The AAP plenary also includes the following sessions:
"Adverse Childhood Experiences, Literacy and Kindergarten Problems," presented by Manuel Jimenez, MD, FAAP, from 12:35-12:50 p.m.
"Viewing as Little as 1 Hour of Television Daily Is Associated with Higher Weight Status in Kindergartners: The Early Childhood Longitudinal Study," presented by Mark DeBoer, MD, MSc, MCR, from 12:50-1:05 p.m.
"Code Switching in English Language Learners from Low-Income Spanish-speaking Homes May Be a Strength Rather Than a Risk," presented by Adriana Weisleder, PhD, from 1:05-1:20 p.m.
"Association Between State Laws Governing School Nutrition and Physical Activity and Subsequent Child Weight Status," presented by Deepak Palakshappa, MD, FAAP, from 1:20-1:35 p.m.
AAP Presidential Address, presented by Sandra Hassink, MD, FAAP, from 1:35-2:05 p.m.
"Provider Delivery of the 5 AsTobacco Intervention to Youth," presented by Julie Gorzkowski, MSW, from 2:30-2:45 p.m.
"ADHD Diagnosis and Stimulant Medication Use in Preschoolers Before and After Publication of the 2011 Practice Guideline," presented by Alexander Fiks, MD, FAAP, from 2:45-3 p.m.
"Patient and Physician Facing Computer Decision Support Dramatically Increases Routine Autism Screening," presented by Stephen Downs, MD, MS, FAAP, from 3-3:15 p.m.
INFORMATION:
The Pediatric Academic Societies (PAS) are four individual pediatric organizations that co-sponsor the PAS Annual Meeting - the American Pediatric Society, the Society for Pediatric Research, the Academic Pediatric Association, and the American Academy of Pediatrics. Members of these organizations are pediatricians and other health care providers who are practicing in the research, academic and clinical arenas. The four sponsoring organizations are leaders in the advancement of pediatric research and child advocacy within pediatrics, and all share a common mission of fostering the health and well-being of children worldwide.For more information, visit http://www.pas-meeting.org. Follow news of the PAS meeting on Twitter at @PASmeeting and Facebook at http://www.facebook.com/pages/Pediatric-Academic-Societies-Annual-Meeting/134020174135. Use hashtag #PASMEETING.
April 25, 2015, Vienna, Austria: New data presented today at The International Liver Congress™ 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT). The results are based on data from patients with HCV being treated with second-generation DAAs in the large French prospective ANRS CO23 CUPILT study. Among them, 296 patients were treated with a combination of SOF+DCV, with or without ribavirin.
SOF- and DCV-based regimens offered high rates of ...
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%, p = 0.008) or 16 weeks ...
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.
The study found that chronic HCV infection has a limited impact on mortality, unless the patient also has other severe comorbidities, such as HIV infection, cancer or chronic kidney disease. In contrast, those with AUDs are at significant risk of death with a higher ...
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.
Overall, the sustained virologic response rate at 4 weeks (SVR4) for SOF/DCV was 81.6% after 12 weeks of treatment and 93.9% ...
April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. Sustained virologic response rates at 12 weeks (SVR12) were >90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV recurrence.
ALLY-1 ...
April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. New data shows that the cirrhosis burden caused by alcohol increased by 11.13% when moving from the moderate to heavy daily drinking (up to one drink/day for women; two drinks/day for men) classification (p END ...
April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.
In the study, treatment naïve non-cirrhotic adults ...
April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015.
The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...
April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.
The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.
PUDs offer a comparable performance ...
April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.
Most individuals with HCV remain asymptomatic, which makes the diagnosis difficult. The study authors used the hypothesis that individuals whose HCV is not diagnosed are less likely to have advanced fibrosis than those who have been diagnosed. They then compared liver fibrosis between respondents of the ...